- Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancerZhang, Q.; Wang, J.; Ouyang, Q.; Wang, X.; Lin, D.; Wang, J.; Gan, L.; Ouyang, Z.; Xu, T.; Liu, Y.; Lv, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trialXu, B.; Yan, M.; Ma, F.; Li, W.; Ouyang, Q.; Tong, Z.; Teng, Y.; Wang, S.; Wang, Y.; Geng, C.; Luo, T.; Zhong, J.; Zhang, Q.; Liu, Q.; Zeng, X.; Sun, T.; Mo, Q.; Dong, F.; Wu, S.; Zhu, X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 11
- The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina studyShao, Z.; Huang, T.; Fan, Z.; Wang, Y.; Yan, X.; Yang, H.; Wang, S.; Pang, D.; Li, H.; Wang, H.; Geng, C.; Huang, L.; Siddiqui, A.; Wang, B.; Xie, B.; Sun, G.; Restuccia, E.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study
5阅读
